Back to dashboard
CommercialPrior AuthHigh impact

Update to Commercial and ACA Medical Benefit Product Coverage for Medical Mutual Plans

Medical Mutual of Ohio·Oncology, Urology, OB-GYN·Medical Policy
Effective date
May 1, 2023
We identified it
Jun 20, 2026
Days to comply

Summary

Medical Mutual now requires prior authorization for Lupron Depot (leuprolide acetate) injections for commercial and ACA plans, with mandatory trial of Eligard first for prostate, ovarian, breast, and head/neck salivary gland cancers. This affects oncology billing workflows starting May 1, 2023.

Action Required

Action needed
Immediately: Billing team must update prior authorization requirements for HCPCS codes J1950 and J9217 (Lupron Depot) for Medical Mutual commercial and ACA plans. Providers must document trial of Eligard before prescribing Lupron for prostate, ovarian, breast, and head/neck salivary gland cancers. Update encounter forms and EMR templates to include prior auth reminders. Claims will be denied without proper authorization.

Affected Billing Codes

J1950
J9217